Status:
COMPLETED
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Conditions:
Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
A real-world prospective registry study for patients with newly diagnosed multiple myeloma (NDMM) has been conducted at the First Affiliated Hospital of Soochow University since August 2018. Diagnosis...
Eligibility Criteria
Inclusion
- (1) diagnosis of active multiple myeloma according to the IMWG criteria; (2) age over 18 years; (3) newly diagnosed and treatment-naïve; (4) availability of complete clinical information; (5) receipt of at least two cycles of VRD regimen; and (6) regular follow-up at our department.
Exclusion
- (1) follow-up duration of less than 6 months; (2) incomplete clinical data; and (3) failure to receive regular treatment in our department.
Key Trial Info
Start Date :
August 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2025
Estimated Enrollment :
419 Patients enrolled
Trial Details
Trial ID
NCT07206810
Start Date
August 1 2018
End Date
February 1 2025
Last Update
October 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital, Soochow University
Suzhou, Jiangsu, China, 215000